Reyes José, Del Priore Isabella, Chaikovsky Andrea C, Pasnuri Nikhita, Elhossiny Ahmed M, Krause Tobias, Moorman Andrew, Snopkowski Catherine, Takizawa Meril, Burdziak Cassandra, Ratnayeke Nalin, Masillioni Ignas, Ho Yu-Jui, Chaligné Ronan, Romesser Paul B, Filliol Aveline, Nawy Tal, Morris John P, Zhao Zhen, Di Magliano Marina Pasca, Alonso-Curbelo Direna, Pe'er Dana, Lowe Scott W
Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Computational and Systems Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
bioRxiv. 2025 Jun 12:2025.06.10.656791. doi: 10.1101/2025.06.10.656791.
The transition from benign to malignant growth is a pivotal yet poorly understood step in cancer progression that marks the shift from a pathologically inert condition to a clinically lethal disease. Here, we integrate lineage tracing, single-cell and spatial transcriptomics to visualize the molecular, cellular and tissue-level events that promote or restrain malignancy during the tumor initiation in mouse models of pancreatic ductal adenocarcinoma (PDAC). We identify a discrete progenitor-like population of -mutant cells that co-activates oncogenic and tumor-suppressive programs-including p53, CDKN2A, and SMAD4-engaging senescence-like responses and remodeling their microenvironment, ultimately assembling a niche that mirrors invasive PDAC. KRAS inhibition depletes progenitor-like cells and dismantles their niche. Conversely, p53 suppression enables progenitor cell expansion, epithelial-mesenchymal reprogramming, and immune-privileged niche formation. These findings position the progenitor-like state as the convergence point of cancer-driving mutations, plasticity, and tissue remodeling-revealing a critical window for intercepting malignancy at its origin.
从良性生长到恶性生长的转变是癌症进展中一个关键但却知之甚少的步骤,它标志着从病理上的惰性状态转变为临床上的致命疾病。在此,我们整合谱系追踪、单细胞和空间转录组学,以可视化在胰腺导管腺癌(PDAC)小鼠模型肿瘤起始过程中促进或抑制恶性肿瘤的分子、细胞和组织水平事件。我们鉴定出一群离散的具有 - 突变的祖细胞样群体,它们共同激活致癌和抑癌程序,包括p53、CDKN2A和SMAD4,引发类似衰老的反应并重塑其微环境,最终形成一个与侵袭性PDAC相似的生态位。KRAS抑制会耗尽祖细胞样细胞并破坏其生态位。相反,p53抑制会使祖细胞扩张、上皮 - 间质重编程以及形成免疫特权生态位。这些发现将祖细胞样状态定位为癌症驱动突变、可塑性和组织重塑的交汇点,揭示了在恶性肿瘤起源时拦截它的关键窗口期。